Drug-use patterns in an intensive care unit of a hospital in Iran: An observational prospective study

International Journal of Pharmacy Practice

Volumn 18, Issue 6, 2010, Pages 370-376

  Tavallaee, Mahkam ^a   Fahimi, Fanak ^b,c   Kiani, Shirin ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

^b SHAHID BEHESHTI UNIVERSITY   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

antibiotics; clinical pharmacy; drug utilization evaluation; ICU; Iran

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIULCER AGENT; BRONCHODILATING AGENT; ENOXAPARIN; HEPARIN; INDOMETACIN; INOTROPIC AGENT; INSULIN; LAXATIVE; PARACETAMOL; SEDATIVE AGENT; STEROID; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; DRUG COST; DRUG USE; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; IRAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL PATIENT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG COSTS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE; INTENSIVE CARE UNITS; IRAN; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PROSPECTIVE STUDIES;

EID: 78649300262     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7174.2010.00065.x     Document Type: Article

References (23)

1. Biswal S, et al. Drug utilization pattern in the Intensive Care Unit of a tertiary care hospital. J Clin Pharmacol 2006; 46: 945.
2. Bernieh B, et al. Outcome and predictive factors of acute renal failure in the intensive care unit. Transplant Proc 2004; 36: 1784 - 1787.
3. Hartmann B, et al. Review of antibiotic drug use in a surgical ICU: management with a patient data management system for additional outcome analysis in patients staying more than 24 hours. Clin Ther 2004; 26: 915 - 924.
4. Romo H, et al. Effect of patient sex on intensive care unit survival. Arch Intern Med 2004; 164: 61 - 65.
5. Weber RJ, et al. Impact of intensive care drug costs: a descriptive analysis, with recommendations for optimizing ICU pharmacotherapy. Crit Care Med 2003; 31: S17 - S24.
6. Ansari F,. Utilization review of systemic antiinfective agents in a teaching hospital in Tehran, Iran. Eur J Clin Pharmacol 2001; 57: 541 - 546.
7. Fowler R, et al. Sex- and age-based differences in the delivery and outcomes of critical care. CMAJ 2007; 177: 1513 - 1519.
8. Knaus WA, et al. Variations in mortality and length of stay in Intensive Care Units. Ann Intern Med 1993; 118: 753 - 761.
9. Wichmann MW, et al. Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 2000; 26: 167 - 172.
10. Vincent JL, et al. The prevalence of nosocomial infection in intensive care units in Europe: the results of the EPIC study. JAMA 1995; 274: 639 - 644.
11. Diodato MD, et al. Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. Cytokine 2001; 14: 162 - 169.
12. Zellweger R, et al. Females in proestrus state maintain splenic immune functions and tolerate sepsis better than males. Crit Care Med 1997; 25: 106 - 110. (Pubitemid 27015048)
13. Schneider CP, et al. The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis. Shock 2000; 14: 347 - 353.
14. Walther SM, et al. for the Icustrama Study Group. Antibiotic prescription practices, consumption and bacterial resistance in a cross section of Swedish intensive care units. Acta Anaesthesiol Scand 2002; 46: 1075 - 1081.
15. Ministry of Health and Medical Education: Food and Drug Department. Announcement # 102: ADR of ceftriaxone. (accessed 19 June 2010) (in Farsi).
16. Allan GM, et al. Physician awareness of drug cost: a systematic review. PLoS Med 2007; 4: 283.
17. Wang YL, et al. Reduction in cost of stay in intensive care unit with price education program of drugs. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2007; 19: 492 - 495 (in Chinese).
18. Rüttimann S, et al. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004; 38: 348 - 356.
19. Radyowijati A, Haak H,. Improving antibiotic use in low-income countries: an overview of evidence on determinants. Soc Sci Med 2003; 57: 733 - 744.
20. Horn E, Jacobi J,. The critical care clinical pharmacist: evolution of an essential team member. Crit Care Med Interface Public Policy Crit Care Med 2006; 34 (Suppl.): S46 - S51.
21. Kane SL, et al. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med 2003; 29: 691 - 698.
22. Leape LL, et al. Pharmacist participation on physician rounds and adverse drug events in the Intensive Care Unit. JAMA 1999; 282: 267 - 270.
23. Salamzadeh J,. Clinical pharmacy in Iran: where do we stand? Iran J Pharm Res 2004; 3: 1 - 2.